OMV-Vacc

Leading Innovation in OMV Technology: 

Engineered OMVs from Neisseria meningitidis

OMV-VACC

At AdJane, we lead innovation in Outer Membrane Vesicle (OMV) technology, building on three decades of pioneering work with Neisseria meningitidis-derived OMVs.

Our team combines deep scientific expertise and advanced engineering to progress multiple vaccine programs through clinical development.

OMVs are non-replicating nanoparticles, carrying strong immune potentiators such as Pathogen-Associated Molecular Patterns (lipopolysaccharide, outer membrane proteins, lipoproteins, etc.), triggering an immune response and enabling protective immunity.

We have genetically engineered Neisseria meningitidis strains to:

  • Improve OMV production yield
  • Reduce reactogenicity
  • Enable antigen presentation

Backed by 7 patent families, our platform is highly versatile, scalable, and ideal for next-generation vaccines.

With one of our programs already clinically validated and compelling data emerging from challenge studies in additional candidates, our platform is positioned to deliver differentiated vaccine solutions.

Explore our Proprietary Platform

Broad Application

OMV-Vacc is applicable for both bacterial and viral vaccines, administration-route-agnostic, and can be utilized in multivalent vaccine concepts. Our platform ensures broad protection – a key milestone in vaccinology.

Strong and durable immunity

After intramuscular or intranasal administration, OMV-Vacc activates the TLR2 and TLR 4 pathways, inducing a balanced, strong, and durable immune response. ADA induces cellular (Th1), humoral (Th2), and mucosal (Th17) immunity.

Safe and well-tolerated

Clinical Phase I study confirms OMV-Vacc’s excellent safety profile with no adverse effects. The modified Neisseria meningitidis OMV’s are specifically engineered to reduce LPS toxicity while preserving adjuvating properties to trigger a natural immune response.

Scalable, high yield, and excellent stability

Our proprietary GMP manufacturing process is optimized for flexible, high-yield, and consistent production of OMVs, that demonstrate exceptional 5+ years stability under standard cold-chain conditions.